Highlights

  • Updated Phase II TRIPP-FFX data met both co-primary study endpoints.
  • Per Protocol analysis reported median overall survival of 21.3 months.
  • The company plans to submit a Change Notification in the second half of 2026.
  • The OncoSil device continues to be evaluated alongside FOLFIRINOX chemotherapy.

OncoSil Medical Limited (ASX:OSL) remained in the spotlight after its shares traded higher on 23 July 2026. While no confirmed company announcement was released on the day, investor attention continued to centre on updated clinical data from the company's Phase II TRIPP-FFX study, which was presented earlier this month at the ESMO Gastrointestinal Cancers Congress (ESMO GI 2026).

The latest results add to the clinical evidence supporting the use of the OncoSil device in patients with unresectable locally advanced pancreatic cancer receiving standard chemotherapy.

Updated Clinical Data Reported at ESMO GI 2026

OncoSil presented updated findings from its TRIPP-FFX Phase II study on 6 July 2026 during ESMO GI 2026 in Munich, Germany.

The study evaluates the company's OncoSil device in combination with FOLFIRINOX chemotherapy for patients with unresectable locally advanced pancreatic cancer (LAPC).

According to the company, the study met both co-primary endpoints, covering safety and tolerability together with local disease control at 16 weeks. No new safety signals were identified during the analysis.

Survival Outcomes Extend Clinical Evidence

The presentation also included a newly reported Per Protocol analysis.

The company reported a median overall survival of 21.3 months for patients treated according to the study protocol.

Within the intent-to-treat population, median overall survival was reported at 18.2 months, while median local progression-free survival reached 12.8 months and median progression-free survival was 12.1 months.

The company also reported a 16-week local disease control rate of 82.2% in the intent-to-treat population and 85.0% in the Per Protocol population.

Regulatory Expansion Planned

Following the updated clinical results, OncoSil intends to submit a Change Notification to its EU and UK Notified Body during the second half of 2026.

The submission seeks to expand the device's approved European label to include use alongside FOLFIRINOX chemotherapy.

The OncoSil device delivers phosphorus-32 (P-32) microparticles directly into pancreatic tumours, providing targeted internal radiation therapy while being used in combination with systemic chemotherapy rather than as a standalone treatment.

Clinical Progress Remains the Primary Focus

OncoSil continues advancing clinical and regulatory activities as it works towards broader commercial adoption of its technology.

The company operates in a specialised area of pancreatic cancer treatment, where therapeutic options remain limited for patients with locally advanced disease.

Although the shares traded higher on 23 July 2026, the TRIPP-FFX results were presented more than two weeks earlier, and no verified evidence directly linked the intraday share-price movement to the earlier clinical presentation.

What Investors May Watch

Investors may monitor progress of the planned Change Notification, further clinical data, peer-reviewed publication of the TRIPP-FFX study, regulatory developments, commercial adoption and future funding updates.

Risks

OncoSil remains a clinical-stage medical device company. Regulatory approvals, commercial adoption, future funding requirements, additional clinical validation and broader market acceptance may influence future performance. Positive Phase II results do not guarantee regulatory or commercial success.